A Randomized Trial of Vitamin D Supplementation and COVID-19 Clinical Outcomes and Long COVID: The Vitamin D for COVID-19 Trial - PubMed
5 hours ago
- #Vitamin D
- #Clinical Trial
- #COVID-19
- A randomized controlled trial evaluated the effect of vitamin D3 supplementation on COVID-19 outcomes and long COVID.
- Participants included adults with newly diagnosed COVID-19 and their close contacts in the U.S. and Mongolia.
- The study compared a vitamin D3 regimen (9600 IU/d for 2 days, then 3200 IU/d for 4 weeks) with a placebo.
- Primary outcome was healthcare utilization or death within 4 weeks among index participants.
- No significant difference was found in healthcare utilization between the vitamin D3 and placebo groups.
- A nonsignificant trend toward reduced long COVID prevalence was observed in per-protocol analyses.
- Vitamin D3 supplementation did not significantly alter COVID-19-related outcomes compared to placebo.
- Further study is warranted for potential benefits of vitamin D3 on long COVID.